Our data is the first to show that in arthritic condition, blockade of IL-17A can disrupt this critical interaction of CXCR4 with SDF-1 by significantly reducing the SDF-1 levels in the bones and lungs and thus inhibiting the migration of the CXCR4+ BC cells towards the metastatic niches. Here, CXCL12 is linked to breast cancer.